Advertisement
Canada markets closed

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7325
    +0.0002 (+0.02%)
     

  • CRUDE OIL

    83.79
    +0.22 (+0.26%)
     

  • Bitcoin CAD

    87,663.40
    -461.81 (-0.52%)
     

  • CMC Crypto 200

    1,381.71
    -0.87 (-0.06%)
     

  • GOLD FUTURES

    2,342.10
    -0.40 (-0.02%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,763.00
    +195.50 (+1.11%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,675.94
    +47.46 (+0.13%)
     

  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     

Biotech Stock Tests Buy Zone, Gets New Approval For Asthma Drug Relvar Ellipta

MATTHEW GALGANI
Updated
Biotech Stock Tests Buy Zone, Gets New Approval For Asthma Drug Relvar Ellipta

GlaxoSmithKline[ticker symb=GSK] partner Innoviva[ticker symb=INVA] is trying to buck the market correction and finish a new base. The biotech stock recently received new European Union approval for Relvar Ellipta, an asthma drug Innoviva developed with GSK. Last month, London-based GSK and California-based Innoviva announced that the European Commission approved a label upgrade for Relvar Ellipta. Known as Breo Ellipta in...

Continue reading